Kodiak Sciences Inc. KOD 深 滬
已收盤 03-27 16:00:00 美东时间
37.00
-2.760
-6.94%
華盛通- 最 高45.60
- 今 開41.89
- 成交量 526.24万股
- 最 低 36.91
- 昨 收 39.76
- 總市值 22.85亿
- 52周最高 45.60
- 市盈率 靜 --
- 換手率 8.52%
- 52周最低 1.92
- 委 比 -19.87%
- 總股本 6175.85万
- 歷史最高 171.21
- 量 比 1.51
- 振 幅 21.86%
- 歷史最低 1.37
- 每 手 1
- 風險率 9.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 眼科新药临床数据大超预期，KOD周涨超 66%；获汉高集团收购，OLPX 周涨近52%
眼科新药临床数据大超预期，KOD周涨超 66%；获汉高集团收购，OLPX 周涨近52%；租车板块景气度提升，安飞士周涨超48%>>
今天 10:06
Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?
Kodiak Sciences Inc (NASDAQ: KOD) shares are trading higher Friday after positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy.
03-27 22:40
U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings
U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings March 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Brown-Forman, Chord Energy and Olaplex Holdings on Friday. HIGHLIGHTS * Brown-Forman Corp BFb.N
03-27 15:54
美股牛股 | 绩优股成避风港！AI软件股Navan暴涨43%；无人机公司Swarmer大涨逾15%
绩优股成避风港！AI软件股Navan暴涨43%、Precigen涨超25%；中东局势再生变数！无人机公司Swarmer隔夜大涨15%>>
03-27 19:20
Kodiak Sciences Stock Hits 52-Week High - Here's Why
Kodiak Sciences (KOD) hits new 52-week high, up 52% after Zenkuda trial success. Get the latest technical analysis, RSI, and support levels.
03-26 23:06
BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan
BUZZ-U.S. STOCKS ON THE MOVE-Corebridge, Robinhood, Navan Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 26 (Reuters) - U.S. stock index futures pointed to a lower open on
03-26 21:26
Kodiak Reports Phase 3 Results For Zenkuda, Study Shows 85% Reduction In Sight-Threatening Complications With Zenkuda Treatment
Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced positive topline results
03-26 18:12
Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham
Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda (tarcocimab tedromer) versus sham in diabetic retinopathy. The primary
03-26 18:02
